Mesoblast (MESO) Reports Strong Revenue Growth for Ryoncil

Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain

NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inf

Honasa Consumer reports nearly 30% revenue growth in Q1 FY27, margins stay in double digits

The parent company of Mamaearth expects consolidated revenue to grow about 30% year-on-year this quarter

Celltrion Poised for Profitability Leap on New Biosimilars

Celltrion is poised for a profitability leap as new biosimilars like Remsima SC and Omlyclo boost its product mix, with Q2 operating profit

StockWatch: Insilico Projects Profit, Revenue Leaps as AI-Developed Lead Candidate Moves to Phase III

Insilico Medicine, an AI-based drug developer whose profile within biopharma has risen with its recent collaborations with industry giants,

Palantir Stock: Accelerating Growth Improves the Risk-Reward Profile

Celltrion's High-Margin Follow-On Products Expand Share in Europe

Celltrion's high-margin follow-on biosimilars are expanding their share across Europe, with Omlyclo reaching 16% and Vegzelma and Yuflyma ho